文章：

评估抗血管生成疗法联合免疫疗法与化疗作为治疗局部晚期及转移性非小细胞肺癌策略的疗效

Evaluation of Anti-Angiogenic Therapy Combined with Immunotherapy and Chemotherapy as a Strategy to Treat Locally Advanced and Metastatic Non-Small-Cell Lung Cancer

原文发布日期：17 December 2024

DOI: 10.3390/cancers16244207

类型: Article

开放获取: 是

英文摘要：

Immunotherapy has made recent improvements in disease-free survival (DFS) and/or overall survival (OS) in all stages of non-small-cell lung cancer (NSCLC). Here, we review the tumor microenvironment and its immunosuppressive effects and discuss how anti-angiogenic therapies may potentiate the anti-carcinogenic effects of immunotherapy. We also review all the past literature and discuss strategies of combining anti-angiogenic therapy and immunotherapy +/− chemotherapy and hypothesize how we can use this strategy for non-small-cell lung cancer in metastatic previously untreated/previously treated settings in previously treated EGFR-mutated NSCLC for the upfront treatment of brain metastases prior to radiation therapy and for the incorporation of this strategy into stage III unresectable disease. We assert the use of anti-angiogenic therapy and immunotherapy when combined appropriately with chemotherapy and radiotherapy has the potential to increase the long-term survivals in both the stage III and metastatic setting so that we can now consider more patients to experience curative treatment.

摘要翻译： 

免疫疗法在非小细胞肺癌（NSCLC）各阶段的治疗中，近期已在无病生存期（DFS）和/或总生存期（OS）方面取得显著进展。本文综述了肿瘤微环境及其免疫抑制作用，并探讨抗血管生成疗法如何增强免疫疗法的抗癌效应。我们系统回顾了既往所有文献，讨论了抗血管生成疗法与免疫疗法联合化疗或不联合化疗的策略，并针对以下临床场景提出假设性应用方案：转移性初治或经治的非小细胞肺癌、既往接受过治疗的EGFR突变型NSCLC、放疗前脑转移灶的前期治疗，以及将该策略整合至III期不可切除疾病治疗中。我们主张，当抗血管生成疗法与免疫疗法在适当时机联合化疗及放疗时，有望提升III期和转移性肺癌患者的长期生存率，从而使更多患者有望获得根治性治疗机会。

原文链接：

Evaluation of Anti-Angiogenic Therapy Combined with Immunotherapy and Chemotherapy as a Strategy to Treat Locally Advanced and Metastatic Non-Small-Cell Lung Cancer